PUBLISHER: The Business Research Company | PRODUCT CODE: 2040079
PUBLISHER: The Business Research Company | PRODUCT CODE: 2040079
Drug-coated balloons (DCBs) for coronary artery disease (CAD) refer to a category of interventional cardiovascular devices designed to treat narrowed or blocked coronary arteries through percutaneous coronary intervention (PCI). The primary purpose of DCBs in CAD treatment is to restore proper blood flow in diseased coronary arteries while minimizing the need for permanent implants like stents.
The drug-coated balloons for coronary artery disease market consists of sales, by entities (organizations, sole traders, or partnerships) that are used by interventional cardiologists and are deployed during PCI procedures commonly performed in hospitals, cardiac catheterization labs and, in some cases, ambulatory surgical centers. They are used at the time of balloon angioplasty, where the device is introduced via catheter, navigated to the lesion, inflated to dilate the artery and concurrently release the drug to prevent re-narrowing.
The global drug-coated balloons for coronary artery disease market was valued at $247.8 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 14.00%.
Higher Exposure To Smoking And Air Pollution
During the historic period, the drug-coated balloons for coronary artery disease market was driven by higher exposure to smoking and air pollution. Rising levels of fine particulate matter (PM2.5), emitted from vehicle exhaust, industrial activities, residential fuel combustion, and open burning, along with exposure to smoking, significantly elevate cardiovascular risk worldwide. Both PM2.5 particles and tobacco smoke contain harmful pollutants small enough to enter the bloodstream, triggering inflammation, endothelial dysfunction, and plaque instability, ultimately increasing the likelihood of developing coronary artery disease. For instance, in June 2024, the American Lung Association, a national organization dedicated to improving lung and cardiovascular health, released updated tobacco-use trend data highlighting significant increases in electronic cigarette usage. From 2014 to 2022, the proportion of adults who had ever used e-cigarettes rose by 56%, increasing from 12.6% to 19.6%, while adult current e-cigarette use grew by 62%, from 3.7% to 6.0%. Moreover, from 2011 to 2022, current use of e-cigarettes increased 667% among middle school students (from 0.6% to 4.6%) and 567% among high school students (from 1.5% to 10.0%). Additionally, in June 2024, the State of Global Air (SoGA), an independent initiative by the Health Effects Institute that provides global assessments of air pollution exposure and associated disease burden, published updated data on PM2.5 pollution and its health impacts for the year 2023, according to the report, PM2.5 exposure contributed to approximately 4.9 million deaths in 2023, making it one of the leading global risk factors for mortality. Therefore, the drug-coated balloons for coronary artery disease market was driven by higher exposure to smoking and air pollution.
Emergence Of Sirolimus-Eluting Drug-Coated Balloons As Advanced Solutions For Coronary Intervention
Major companies in the drug-coated balloons for coronary artery disease market are focusing on the development of sirolimus-eluting drug-coated balloons (DCBs) designed to provide enhanced vessel healing and broaden treatment options for both de novo lesions and in-stent restenosis. These advancements emphasize improved drug-release profiles, reduced inflammatory response and greater procedural flexibility, while offering clinicians implant-free solutions that align with evolving interventional strategies. For instance, in October 2025, Cordis, a US-based global cardiovascular device manufacturer, showcased new clinical data on its sirolimus-eluting balloon at the TCT 2025 conference, highlighting its performance in large, randomized studies evaluating outcomes in patients with both de novo coronary artery disease and in-stent restenosis. The reported results demonstrated non-inferiority to standard drug-eluting stent treatments, while also showing the potential to eliminate the need for permanent implants in a significant portion of patients. By utilizing advanced sirolimus-delivery technology and robust multi-trial clinical evidence, the company aims to support wider adoption of DCB solutions and to meet the evolving requirements of global coronary intervention markets.
The global drug-coated balloons for coronary artery disease market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 81.98% of the total market in 2024.
Drug-Coated Balloons For Coronary Artery Disease Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global drug-coated balloons for coronary artery disease market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for drug-coated balloons for coronary artery disease ? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The drug-coated balloons for coronary artery disease market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider drug-coated balloons for coronary artery disease market; and compares it with other markets.